310 related articles for article (PubMed ID: 24361860)
1. A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.
Bennetto-Hood C; Tabolt G; Savina P; Acosta EP
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 945-946():225-32. PubMed ID: 24361860
[TBL] [Abstract][Full Text] [Related]
2. High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples.
Tsuchiya K; Ohuchi M; Yamane N; Aikawa H; Gatanaga H; Oka S; Hamada A
Biomed Chromatogr; 2018 Feb; 32(2):. PubMed ID: 28762239
[TBL] [Abstract][Full Text] [Related]
3. The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.
Penchala SD; Fawcett S; Else L; Egan D; Amara A; Elliot E; Challenger E; Back D; Boffito M; Khoo S
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():174-80. PubMed ID: 27290668
[TBL] [Abstract][Full Text] [Related]
4. UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.
Simiele M; Ariaudo A; De Nicolò A; Favata F; Ferrante M; Carcieri C; Bonora S; Di Perri G; De Avolio A
J Pharm Biomed Anal; 2017 May; 138():223-230. PubMed ID: 28219799
[TBL] [Abstract][Full Text] [Related]
5. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
Yamada E; Takagi R; Moro H; Sudo K; Kato S
PLoS One; 2021; 16(2):e0246994. PubMed ID: 33600473
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma.
Bollen PDJ; de Graaff-Teulen MJA; Schalkwijk S; van Erp NP; Burger DM
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():76-84. PubMed ID: 30572204
[TBL] [Abstract][Full Text] [Related]
7. A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma.
Srivastava P; Moorthy GS; Gross R; Barrett JS
PLoS One; 2013; 8(6):e63305. PubMed ID: 23755102
[TBL] [Abstract][Full Text] [Related]
8. A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.
Long MC; Bennetto-Hood C; Acosta EP
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 May; 867(2):165-71. PubMed ID: 18430616
[TBL] [Abstract][Full Text] [Related]
9. A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection.
Wang X; Penchala SD; Amara A; Else L; McClure M; Boffito M
Ther Drug Monit; 2016 Jun; 38(3):327-31. PubMed ID: 26859200
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous quantification of five antiretrovirals in human tissues using ultra-high performance liquid chromatography-tandem mass spectrometry methods for therapeutic drug monitoring at the sites of action.
West RE; Oberly PJ; Saylor AJ; Riddler SA; Nolin TD; Devanathan AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jul; 1241():124164. PubMed ID: 38823149
[TBL] [Abstract][Full Text] [Related]
11. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS.
Merschman SA; Vallano PT; Wenning LA; Matuszewski BK; Woolf EJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 857(1):15-24. PubMed ID: 17644453
[TBL] [Abstract][Full Text] [Related]
12. Validation of an LC-MS/MS assay for the simultaneous determination of bictegravir, doravirine, and raltegravir in human plasma.
Schauer AP; Sykes C; Cottrell ML; Imaz A; Podzamczer D; Kashuba AD
J Pharm Biomed Anal; 2022 Oct; 220():115010. PubMed ID: 36030752
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
14. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
15. Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry.
Ter Heine R; Hillebrand MJ; Rosing H; van Gorp EC; Mulder JW; Beijnen JH; Huitema AD
J Pharm Biomed Anal; 2009 Feb; 49(2):451-8. PubMed ID: 19128911
[TBL] [Abstract][Full Text] [Related]
16. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M
PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886
[TBL] [Abstract][Full Text] [Related]
17. Comparison of bioanalytical methods for the quantitation of PEGylated human insulin.
de Dios K; Manibusan A; Marsden R; Pinkstaff J
J Immunol Methods; 2013 Oct; 396(1-2):1-7. PubMed ID: 23933323
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
19. A liquid chromatography-tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasma.
Grégoire M; Deslandes G; Renaud C; Bouquié R; Allavena C; Raffi F; Jolliet P; Dailly E
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Nov; 971():1-9. PubMed ID: 25261833
[TBL] [Abstract][Full Text] [Related]
20. Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
Djerada Z; Feliu C; Tournois C; Vautier D; Binet L; Robinet A; Marty H; Gozalo C; Lamiable D; Millart H
J Pharm Biomed Anal; 2013 Dec; 86():100-11. PubMed ID: 23995753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
